Acquired chemotherapy resistance in ovarian cancer
EL Christie, DDL Bowtell
ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2017
Most women diagnosed with high-grade serous ovarian cancer (HGSC) develop recurrent disease and chemotherapy resistance, despite initially responding to treatment. The genomic characteristics of HGSC samples collected at initial surgery have been extensively studied. However, due to challenges of sample collection following treatment, much less is known about the molecular features of recurrent disease. Our recent studies have identified mechanisms of acquired resistance and biomarkers in recurrent HGSCs that could lead to improved treatment approaches.
Related Projects (4)
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by NHMRC
Awarded by Victorian Cancer Agency
Awarded by U.S. Army Medical Research and Materiel Command
Awarded by National Health and Medical Research Council of Australia (NHMRC)
This work was supported by a National Health and Medical Research Council (NHMRC) program grant (APP1092856; to D.D.L. Bowtell), NHMRC project grant (GNT1124309; to E. Christie) and a Victorian Cancer Agency Early Career Seed Grant (ECSG15012; to E. Christie). The Australian Ovarian Cancer Study is supported by the Peter MacCallum Cancer Centre Foundation, U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, The Cancer Council Tasmania, and the National Health and Medical Research Council of Australia (NHMRC; ID#628779), and Ovarian Cancer Australia. The publication of this supplement and the symposium on which it is based have been supported through partnership between the Spanish Ovarian Cancer Research Group (GEICO) and the European Society for Medical Oncology (ESMO).